Tickertape - Financial freedom begins here

Zydus Lifesciences has launched 'Zyrifa', a Denosumab biosimilar. Denosumab is a monoclonal antibody with several indications related to bone health, primarily in the treatment of osteoporosis and the prevention of skeletal complications in cancer patients. This will provide access and treat patients with bone metastases due to breast, prostate, lung, myeloma, kidney, thyroid, head & neck, and other solid tumours. Metastases, is when the cancer spreads to the bones and other organs in the body indicating an advanced stage of cancer. 'Zyrifa' is priced at MRP of Rs 12,495. Speaking on this launch, Dr. Sharvil P. Patel, Managing Director, Zydus Lifesciences, said 'With Denosumab 120 mg SC, we aim to bring access, affordability of medication in cancer patients needing critical care. This will help patients to retain mobility, and support them in their fight against cancer' Zydus Lifesciences Limited has been launching a wide range of biosimilars to treat various cancers ranging from breast cancer to prostate cancer, various other solid tumours and blood cancer. The company has also partnered with diagnostic companies.Powered by Capital Market - Live

The stock was listed at Rs 140, exhibiting a premium of 12.9% to the issue price. So far, the stock has hit a high of 148 and a low of 135.50. On the BSE, over 29.33 lakh shares of the company were traded in the counter so far. The initial public offer of Aequs was subscribed 101.63 times. The issue opened for bidding on 03 December 2025 and it closed on 05 December 2025. The price band of the IPO is fixed between Rs 118 and 124 per share. The offer comprised a fresh issue of equity shares worth up to Rs 670 crore and an offer for sale (OFS) of 2,03,07,393 equity shares by promoter and investor shareholders. The OFS includes 14,23,500 shares from promoter entities and 1,88,83,893 shares from investor shareholders, including Amicus Capital funds and other individual holders. Of the net proceeds from the issue, the company proposes to deploy Rs 433.167 crore towards repayment and/or prepayment, in full or in part, of certain outstanding borrowings and prepayment penalties, as applicable, availed by the company or its subsidiaries; Rs 64.002 crore towards funding capital expenditure to be incurred on account of purchase of equipment by the company and Aero Structures Manufacturing India, a WoS of the company; and the balance towards funding inorganic growth through unidentified acquisitions, other strategic initiatives, and general corporate purposes. Aequs is a vertically integrated precision manufacturing company focused primarily on the aerospace sector, with niche capabilities in machining high-end alloys such as titanium. It offers end-to-end solutions'from machining and forging to surface treatment and assembly'and operates one of India's most advanced aerospace manufacturing ecosystems. Aerospace contributed approximately 89% of FY25 revenue, with the business largely export-driven, while the consumer segment includes cookware, appliances, toys, and electronics components. Ahead of the IPO, Aequs, on 2 December 2025, raised Rs 413.91 crore from anchor investors. The board allotted 33.38 lakh shares at Rs 124 each to 33 anchor investors. The firm reported a consolidated net loss of Rs 20.07 crore and an income from operations of Rs 537.16 crore for the six months ended on 31 March 2025.Powered by Capital Market - Live

Under the agreement, Zaggle will offer Mastercard credit cards and related solutions to its customers and prospects and will receive additional spend-linked incentives. The company stated that the contract is valid for five years. It also clarified that neither its promoters nor members of the promoter group have any interest in the awarding authority, confirming that the agreement does not qualify as a related-party transaction under regulatory norms. Zaggle Prepaid Ocean Services (Zaggle) is a leading player in spend management, with a differentiated value proposition and diversified user base. The company operates in the business-to-business-to-customer segment. It is one of the largest numbers of issued prepaid cards in India in partnership with its banking partners. Additionally, the company has a diversified portfolio of software as a service (SaaS) products, including tax and payroll software, and a wide touchpoint reach. The company's standalone net profit surged 79.1% to Rs 33.24 crore on a 42.4% rise in revenue from operations to Rs 430.98 crore in Q2 FY26 over Q2 FY25. Powered by Capital Market - Live